| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8444567 | European Journal of Cancer | 2013 | 7 Pages |
Abstract
KRN330 is safe and tolerable at the MTD of 3Â mg/kg once weekly in patients with advanced CRC. Dosing on alternate weeks is supported by tumour binding. The long treatment durations and lack of immunogenicity warrant further investigation of KRN330 in combination.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jeffrey R. Infante, Johanna C. Bendell, Laura Williams Goff, Suzanne F. Jones, Emily Chan, Tomohiro Sudo, Howard A. Burris, Jordan D. Berlin,